BioSpace News Archive

Believing that a viable Bayonne Medical Center is vital to its community, BMC Hospital LLC has signed a letter of intent with CarePoint Health to purchase the Center and work closely with all stakeholders to strengthen its long-term success as an acute care facility in the service of Bayonne.

Bardy Diagnostics, Inc. announced that its Carnation Ambulatory Monitor Patch has been chosen for use in protocols to measure QT Segments in COVID-19 patients who have been prescribed Hydroxychloroquine.

Greenbrook TMS Inc. provides the following update regarding the impact of the COVID-19 pandemic on Greenbrook’s business and its response to dealing with the pandemic.

RPM with Medics Telemedicine Creates a Comprehensive Combination of Virtual Diagnostics for Providers and Patients

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) today provided an update on its 2016 collaboration agreement with Celgene Corporation, a wholly owned subsidiary of Bristol Myers Squibb Company.

Xencor, Inc. announced it has entered into a technology license agreement with Vir Biotechnology, Inc., in which Vir will have non-exclusive access to Xencor’s Xtend™ Fc technology to extend the half-life of novel antibodies that Vir is investigating as potential treatments for patients with COVID-19, the disease caused by the novel coronavirus SARS-CoV-2.

Viracta Therapeutics, Inc. announced the appointment of Lisa Rojkjaer, MD, as Chief Medical Officer, effective May 1, 2020.

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the year ended December 31, 2019 and host a conference call on Friday, March 27, 2020.

Further to its press release of March 20, 2020, Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech” or the “Company) announced that, in response to the evolving dynamics related to the COVID-19 pandemic, it has decided to delay the release of its fourth quarter and full year 2019 financial results, originally scheduled for March 26, 2020, until after market close on Thursday, April 2, 2020.

Evofem Biosciences, Inc. announced that its Board of Directors has adopted a shareholder rights agreement, effective March 24, 2020, under which its stockholders will receive a dividend in the form of preferred stock purchase rights.